Our findings add to the growing complexity of NUTM1 rearrangement’s role in hematologic malignancies and raise the possibility that the nature of the NUTM1 fusion partner or disease biology may influence the treatment response and clinical outcomes. Here, NUTM1 is linked to hematologic disorder.